• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Dianthus Therapeutics Inc.

    3/11/25 4:09:33 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNTH alert in real time by email
    S-8 1 dnth-form_s-8-2025.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 11, 2025

    Registration No. 333- 

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

     

     

     

     

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

     

     

     

     

     

     

     

    Dianthus Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

     

    Delaware

     

    81-0724163

     

     

    (State or Other Jurisdiction of

    Incorporation or Organization

     

    (I.R.S. Employer

    Identification No.)

     

     

     

     

     

     

     

     

     

     

     

     

    7 Times Square, 43rd Floor

    New York, NY 10036

     

     

    (Address of Principal Executive Offices, Zip Code)

     

     

     

     

     

     

     

     

     

     

     

    Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan

    Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended

     

     

    (Full title of the plan)

     

     

     

     

     

     

     

     

     

     

     

     

    Adam M. Veness, Esq.

    Senior Vice President, General Counsel and Secretary

    Dianthus Therapeutics, Inc.

    7 Times Square, 43rd Floor

    New York, NY 10036

    (929) 999-4055

     

     

     

     

     

     

     

    Copies to:

     

     

    Ryan A. Murr, Esq.

    Branden C. Berns, Esq.

    Gibson, Dunn & Crutcher LLP

    One Embarcadero Center, Suite 2600

    San Francisco, CA 94111

    Telephone: (415) 393-8200

    Facsimile: (415) 393-8306

     

     

     

     

     

     

     

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) registers (i) 1,555,767 additional shares of common stock, $0.001 par value per share (“Common Stock”), of Dianthus Therapeutics, Inc. (the “Registrant”) under the Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the “Incentive Plan”), and (ii) 62,500 additional shares of Common Stock under the Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended (the “ESPP”).

    The number of shares of Common Stock reserved and available for issuance under the Incentive Plan is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of Common Stock as determined by the Administrator (as defined in the Incentive Plan). Accordingly, on January 1, 2025, the number of shares of Common Stock reserved and available for issuance under the Incentive Plan increased by 1,555,767 shares. The additional shares are of the same class as other securities relating to the Incentive Plan for which the Registrant’s registration statement filed Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2024, March 21, 2024, October 4, 2023, March 8, 2022, March 3, 2021, March 3, 2020, March 19, 2019 and June 22, 2018 (Registration Nos. 333-281381, 333-278151, 333-274865, 333-263358, 333-253815, 333-236853, 333-230387, and 333-225838), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the Incentive Plan are in addition to the shares of Common Stock registered on such registration statements.

    The number of shares of Common Stock reserved and available for issuance under the ESPP is subject to an automatic annual increase on each January 1 by an amount equal to the least of (i) 1% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, (ii) 62,500 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in the ESPP). Accordingly, on January 1, 2025, the number of shares of Common Stock reserved and available for issuance under the ESPP increased by 62,500. The additional shares are of the same class as other securities relating to the ESPP for which the Registrant’s registration statement filed on Form S-8 filed with the SEC on March 21, 2024, March 8, 2022 and August 8, 2019 (Registration Nos. 333-278151, 333-263358 and 333-233125), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the ESPP are in addition to the shares of Common Stock registered on such registration statements

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information

    The documents containing the information specified in Part I of this Registration Statement will be delivered to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the instructions to Part I of Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit

    Number

     

    Description

    4.1

     

    Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 12, 2023)

    4.2

     

    Third Amended and Restated By-laws (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 21, 2024)

    5.1*

     

    Opinion of Gibson, Dunn & Crutcher LLP

    23.1*

     

    Consent of Deloitte & Touche LLP, independent registered public accounting firm

    23.2*

     

    Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1)

    24.1*

     

    Power of Attorney (included on the signature page to this Registration Statement)


     

    99.1

     

    Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 28, 2024)

    99.2

     

    Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024)

    107.1*

     

    Filing Fee Table

     

    * Filed herewith.

     


     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 11, 2025.

     

     

    DIANTHUS THERAPEUTICS, INC.

     

     

     

    By:

    /s/ Ryan Savitz

     

    Name:

    Ryan Savitz

     

    Title:

    Chief Financial Officer and Chief Business Officer

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Marino Garcia, Ryan Savitz and Adam Veness and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

     

    Signature

     

    Title

    Date

     

     

     

     

    /s/ Marino Garcia

     

    Chief Executive Officer, President and Director

    March 11, 2025

    Marino Garcia

     

    (Principal Executive Officer)

     

     

     

     

     

    /s/ Ryan Savitz

     

    Chief Financial Officer and Chief Business Officer

    March 11, 2025

    Ryan Savitz

     

    (Principal Financial Officer)

     

     

     

     

     

    /s/ Edward Carr

     

    Chief Accounting Officer

    March 11, 2025

    Edward Carr

     

    (Principal Accounting Officer)

     

     

     

     

     

    /s/ Alison F. Lawton

     

    Director and Chair of the Board

    March 11, 2025

    Alison F. Lawton

     

     

     

     

     

     

     

    /s/ Sujay Kango

     

    Director

    March 11, 2025

    Sujay Kango

     

     

     

     

     

     

     

    /s/ Anne McGeorge

     

    Director

    March 11, 2025

    Anne McGeorge

     

     

     

     

     

     

     

    /s/ Leon O. Moulder, Jr.

     

    Director

    March 11, 2025

    Leon O. Moulder, Jr.

     

     

     

     

     

     

     

    /s/ Steven Romano

     

    Director

    March 11, 2025

    Steven Romano

     

     

     

     

     

     

     

    /s/ Paula Soteropoulos

     

    Director

    March 11, 2025

    Paula Soteropoulos

     

     

     

     

     

     

     

    /s/ Jonathan Violin

     

    Director

    March 11, 2025

    Jonathan Violin

     

     

     

     


    Get the next $DNTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNTH

    DatePrice TargetRatingAnalyst
    12/20/2024Buy
    TD Cowen
    10/3/2024$48.00Outperform
    Oppenheimer
    7/26/2024$58.00Outperform
    Robert W. Baird
    6/27/2024Overweight
    Cantor Fitzgerald
    5/16/2024$40.00Buy
    H.C. Wainwright
    2/15/2024$44.00Buy
    Stifel
    12/26/2023$22.00Buy
    Jefferies
    11/22/2023$23.00Outperform
    Wedbush
    More analyst ratings

    $DNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Dianthus Therapeutics

      TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy

      12/20/24 7:31:45 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Dianthus Therapeutics with a new price target

      Oppenheimer initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $48.00

      10/3/24 7:28:24 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Dianthus Therapeutics with a new price target

      Robert W. Baird initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $58.00

      7/26/24 7:27:12 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Dianthus Therapeutics Inc.

      SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      12/3/24 9:19:18 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Dianthus Therapeutics Inc.

      SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      11/22/24 4:41:50 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

      SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      11/14/24 5:48:32 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kango Sujay

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      3/5/25 5:02:30 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kango Sujay

      3 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      3/5/25 5:01:01 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Carr Edward

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      2/4/25 4:27:25 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Dianthus Therapeutics Inc.

      10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      5/12/25 4:14:25 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      5/12/25 4:10:02 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Dianthus Therapeutics Inc.

      SCHEDULE 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      5/12/25 10:28:12 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    Leadership Updates

    Live Leadership Updates

    See more

    $DNTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

      Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co

      3/5/25 7:00:00 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

      Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.

      11/29/23 4:05:00 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

      Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE'26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $331.5 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage

      5/12/25 4:01:46 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

      MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, potent classical pathway inhibitor intended as a self-administered autoinjector dosed once every two weeks NEW YORK and WALTHAM, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced completion of enrollment in the Phase 2 MaGic trial of DNTH

      5/5/25 7:00:00 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics to Participate in Two Upcoming Investor Events

      NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events. Baird Biotech Discovery Series - Marino Garcia, Chief Executive Officer, will participate in a fireside chat webcast on Tuesday, May 6 at 1:30 p.m. EDT.Bank of America 2025 Health Care Conference – Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, May 14 at 5:35 p.m. EDT / 2:35 p.m. PDT and will host one-on-one meeting

      4/29/25 7:00:00 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care